About: Primum non nocere – Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Primum non nocere – Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Primum non nocere – Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?
Creator	Biguetti, Claudia Brotto, Marco Toledo, Mauro
Source	Medline; PMC
abstract	Chloroquine (CQ) and its analog hydroxychloroquine (HCQ) were recently included in several clinical trials as potential prophylactic and therapeutic options for SARS-COV-2 infection/covid-19. However, drug effectiveness in preventing, treating, or slowing the progression of the disease is still unknown. Despite some initial promising in vitro results, rigorous pre-clinical animal studies and randomized clinical trials have not been performed yet. On the other hand, while the potential effectiveness of CQ/HCQ is, at best, hypothetical, their side effects are factual and most worrisome, particularly when considering vulnerable groups of patients being treated with these drugs. in this comment, we briefly explain the possible mechanisms of action of CQ/HCQ for treating other diseases, possible actions against covid-19, and their potent side effects, in order to reinforce the necessity of evaluating the benefit-risk balance when widely prescribing these drugs for SARS-COV-2 infection/covid-19. We conclude by strongly recommending against their indiscriminate use.
has issue date	2020-06-26(xsd:dateTime)
bibo:doi	10.11606/s1518-8787.2020054002631
bibo:pmid	32638884
has license	cc-by
sha1sum (hex)	39ba3347fafe062c68f2407def86554e0c8a8e2d
schema:url	https://doi.org/10.11606/s1518-8787.2020054002631
resource representing a document's title	Primum non nocere – Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?
has PubMed Central identifier	PMC7319500
has PubMed identifier	32638884
schema:publication	Revista de saude publica
resource representing a document's body	covid:39ba3347fafe062c68f2407def86554e0c8a8e2d#body_text
is schema:about of	named entity 'infection' named entity 'HCQ' named entity 'covid-19' named entity 'mechanisms of action' named entity 'covid-19' named entity 'treatment options' named entity 'SARS-CoV-2' named entity 'Angiotensin-converting enzyme' named entity 'SARS-Cov-2' named entity 'septic shock' named entity 'Brazil' named entity 'lysosomal' named entity 'HCQ' named entity 'HCQ' named entity 'viral infection' named entity 'endosomal' named entity 'proximal' named entity 'covid-19' named entity 'rheumatic diseases' named entity 'oral administration' named entity 'malaria' named entity 'leukocytes' named entity 'present progressive' named entity 'IL6' named entity 'autoimmune diseases' named entity 'cardiomyopathy' named entity 'SARS-CoV-2' named entity 'prophylactic' named entity 'autophagosomes' named entity '2019-nCoV' named entity 'United States' named entity 'erythrocytes' named entity 'pro-inflammatory cytokines' named entity 'covid-19' named entity 'parasite' named entity 'clinical studies' named entity 'antiviral activity' named entity 'leukocytes' named entity 'FDA' named entity 'receptor' named entity 'immune response' named entity 'covid-19' named entity 'HCQ' named entity 'covid-19' named entity 'cardiac effects' named entity 'cell-based' named entity 'off-label' named entity 'coronavirus' named entity 'mechanisms of action' named entity 'inhibit viral entry' named entity 'SARS-CoV-2' named entity 'hydroxychloroquine' named entity 'Vero E6' named entity 'QT prolongation' named entity 'HCQ' named entity 'evolution' named entity 'pre-clinical' named entity 'HCQ' named entity 'dyspnea' named entity 'inflammatory response' named entity 'infection' named entity 'lupus' named entity 'acute poisoning' named entity 'kidney' named entity 'SARS-CoV-2' named entity 'self-medicate' named entity 'National Institutes of Health' named entity 'clinical studies' named entity 'heme' named entity 'primum non nocere' named entity 'TNFα' named entity 'covid-19' named entity 'cardiac muscle cells' named entity 'older adults' named entity 'leukocytes' named entity 'HCQ' named entity 'SARS-Cov-2' named entity 'muscle weakness' named entity 'post exposure prophylaxis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software